Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia

PHASE2TerminatedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

August 31, 2014

Conditions
Dyslipidemia
Interventions
DRUG

PRC-4016

DRUG

Placebo

DRUG

Statins

Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)

Trial Locations (29)

19446

Green and Seidner Family Practice Associates, Lansdale

23294

National Clinical Research - Richmond, Inc., Richmond

23502

National Clinical Research - Norfolk, Inc., Norfolk

27262

Peters Medical Research, High Point

27609

PMG Research of Raleigh, LLC, Raleigh

32127

Progressive Medical Research, Port Orange

32223

Jacksonville Impotence Treatment Center, Jacksonville

32765

Compass Research East, LLC, Oviedo

33606

Meridien Research- Tampa, Tampa

33709

Meridien Research, St. Petersburg

35662

Terence Hart, MD, Muscle Shoals

35801

Medical Affiliated Research Center, Inc., Huntsville

40213

Louisville Metabolic and Atherosclerosis Research Center (L-MARC), Louisville

43213

Columbus Clinical Research, Inc., Columbus

43302

PSB Research/P. S. Bains, M.S., D.O., Marion

RAS Health Ltd, Marion

45219

Sterling Research Group, Ltd. - Auburn, Cincinnati

45227

Metabolic and Atherosclerosis Research Center, Cincinnati

47714

Medisphere Medical Research Center, Evansville

48098

Troy Internal Medicine, P.C., Troy

55435

Radiant Research - Edina, Edina

60201

Evanston Premier Healthcare Research LLC, Evanston

67114

Heartland Research Assoc., LLC, Newton

78404

Padre Coast Clinical Research, Corpus Christi

90057

National Research Institute - Wilshire, Los Angeles

90211

Pacific Oaks Medical Group, Beverly Hills

91978

Encompass Clinical Research, Spring Valley

92705

Research Across America - Santa Ana, Santa Ana

97404

Willamette Valley Clinical Studies, Eugene

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pronova BioPharma

INDUSTRY

NCT01972178 - Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia | Biotech Hunter | Biotech Hunter